慢性丙型肝炎患者抗病毒治疗中肝功能与病毒学应答的关系

doi:10.13481/j.1671-587x.20160120

Abstract

Abstract:

Objective: To explore the changes of liver function in the patients with chronic hepatitis C(CHC)received interferon alpha 2b(INF-α2b)combined with ribavirin therapy,and to study the relationship between the different virological response patterns and liver function. Methods: 264 CHC patients were enrolled. All patients received INF-α2b (5 000 000 U,every other day,subcutaneous injection)combined with ribavirin(15 mg·kg^-1·d^-1,oral)for 48 weeks. The serum HCV RNA level and liver function were assessed at different time points. According to the outcome,the patients were divided into sustained virological response(SVR),breakthrough,relapse and no response(NR)groups. The relationship between the liver function changes and response in the patients with CHC in various groups before and after treatmentwas compared. Results: Among 264 patients,171 patients (64.8%)achieved SVR,37 patients (14.0%)were breakthrough,47 patients(17.8%)were relapse and 9 patients(3.4%)were NR. Compared with breakthrough group,the patients with moderately elevated alanine transaminase(ALT)level in SVR group were easy to achieve SVR than the patients with normal ALT level(P<0.05). After antiviral treatment,the serum ALT and aspartate transaminase (AST)levels were decreased in all patients,especialy at the 12th week and there were significant differences compared with before treatment (P<0.05). The serum ALT and AST levels of the patients in breakthrough group were increased again at the 48th week. In relapse group,the serum ALT and AST levels of the patients were increased again at the 24th week after drug withdrawal. Untill to the 24th week after drug withdrawal,the serum ALT and AST levels were stable in SVR group. Compared with breakthrough group,the serum ALT and AST levels had the greatest reduction at the 12th week in SVR group(P<0.05). The serum ALT and AST levels of the patients in NR group were always higher than those in SVR,breakthrough and relapse groups(P<0.05).Compared with before treatment,the serum total bilirubin(TBIL)and direct bilirubin(DBIL)levels were decreased obviously at the 12th week and maintained stable untill to the 24th week after drug withdrawal in SVR group. At the 24th week,the levels of serum TBIL and DBIL in NR group were significantly higher than those in SVR,breakthrough and relapse groups(P<0.05). Conclusion: The baseline ALT level may associate with the virological response in the CHC. There is an improvement in liver function following antiviral treatment,especially in the patients who achieved SVR.When the HCV have a relapse or breakthrough,transaminase could increase again.

Key words: hepatitis C,chronic, antiviral treatment, virological response, liver function

CLC Number:

R512.63

KONG Wenli, YANG Yiliang, XU Hongqin, PENG Shanshan, HUA Rui, PAN Yu, NIU Junqi. Relationship between liver functionand virological response in patients with chronic hepatitis C during antiviral treatment[J].Journal of Jilin University Medicine Edition, 2016, 42(01): 99-103.

References

[1] Ansaldi F,Orsi A,Sticchi L,et al.Hepatitis C virus in the new era: Perspectives in epidemiology,prevention,diagnostics and predictors of response to therapy[J].World J Gastroenterol,2014,20(29):9633-9652.

[2] 中华医学会肝病学分会,中华医学会传染病与寄生虫病学分会.丙型肝炎防治指南[J].中华肝脏病杂志,2004,12(4):194-198.

[3] 赵辉,谢尧,李明慧.慢性丙型肝炎患者的血清HCV基因型和RNA含量与ALT和AST水平不相关[J].中华检验医学杂志,2007,30(6):631-634.

[4] Mauss S,Hueppe D,John C, et al.Estimating the likelihood of sustained virological response in chronic hepatitis C therapy[J].J Viral Hepat,2011,18(4):e81-e90.

[5] MarcianoS,Borzi SM,Dirchwolf M,et al.Pre-treatment prediction of response to peginterferon plus ribavirin in chronic hepatitis C genotype 3[J].World J Hepatol,2015,7(4): 703-709.

[6] Kainuma M,Furusyo N, Azuma K,etal.Pegylated interferon α-2b plus ribavirin for Japanese chronic hepatitis C patients with normal alanine aminotransferase[J].Hepatol Res,2012,42(1): 33-41.

[7] Hiramatsu N,Inoue Y,Oze T,etal.Efficacy of pegylated interferon plus ribavirin combination therapy for hepatitis C patients with normal ALT levels: a matched case-control study[J].J Gastroenterol,2011,46(11): 1335-1343.

[8] Tohra SK,Taneja S,Ghosh S,et al.Prediction of sustained virological response to combination therapy with pegylated interferon alfa and ribavirin in patients with genotype 3 chronic hepatitis C[J].Dig Dis Sci,2011,56(8):2449-2455.

[9] Zuberi BF,Zuberi FF,Memon SA,et al.Sustained virological response based on rapid virological response in genotype-3 chronic hepatitis C treated with standard interferon in the Pakistani population[J].World J Gastroenterol,2008,14(14):2218-2221.

[10] Liu CH,Liu CJ,Lin CL, et al.Pegylated interferon-α-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter,randomized controlled trial[J].Clin Infect Dis,2008,47(10):1260-1269.

[11] 方超萍,张薇薇,孙小波,等.丙型肝炎患者不同病毒载量与病毒学应答及肝功能改变的相关性[J].现代检验医学杂志,2012,27(5):18-21

[12] Strader DB,Wright T,Thomas DL,et al.Diagnosis,management,and treatment of hepatitis C[J].Hepatology,2004,39(4):1147-1171.

[13] 黄毛山,王秋英,方玉才,等.379例HCV感染者丙型肝炎病毒载量与抗HCV及肝功能指标的相关性分析[J].中华实验和临床病毒学杂志,2014,28(4):291-293.

[14] 王盟,郑伟阳,张红宇,等.聚乙二醇干扰素α-2a与干扰素α-2a治疗慢性丙型肝炎的短期疗效分析[J].中华肝脏病杂志,2014,22(4):255-259.

[15] Gidding HF,Law MG,Amin J, et al.Hepatitis C treatment outcomes in Australian clinics[J].Med J Australia,2012,196(10):633-637.

[16] Turbide C,Soulellis C,Deschenes M,et al.Does a rapid decline in the hematological and biochemical parameters induced by interferon and ribavirin combination therapy for the hepatitis C virus predict a sustained viral response[J].Can J Gastroenterol,2008,22(2):149-152

[17] Mohamed AA,Amin MA,Ragab MM,et al.Protein kinase expression as a predictive factor for interferon response in chronic hepatitis C patients[J].J Adv Res,2014,5(1): 117-123.

[18] 于国英,黄群,马玉秀.慢性丙型肝炎抗病毒治疗进展[J].临床肝胆病杂志,2015,31(4):626-629.

[19] 张丹丹,叶佩燕,黄玉仙,等.慢性丙型肝炎患者获得快速病毒学应答的预测因素分析[J].临床肝胆病杂志,2014,30(12):1310-1314.

Relationship between liver functionand virological response in patients with chronic hepatitis C during antiviral treatment

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 3

Metrics

Comments

Recommended 0

[1]	WEI Yanhong, SONG Shuai, GENG Hui, DIAO Binbin, YANG Guangmin. Clinical significance of detection of alpha 1-microglobulin in serum of patients with chronic hepatitis B [J]. Journal of Jilin University Medicine Edition, 2017, 43(01): 96-100.
[2]	CHEN Qian,QI Chuan-wang,ZHANG Hui,ZHANG Peng,WU Rui-hong,CHI Xiu-mei,YU Ge,PAN Yu,NIU Jun-qi. Thyroid function of patients with chronic hepatitis C after antiviral treatment: dynamic changes,prognosis and influencing factors [J]. Journal of Jilin University Medicine Edition, 2014, 40(03): 641-644.
[3]	ZHANG Hai-shan,ZHANG Xue-wen, MA Shu-rong,ZHANG De-heng，QIU Dong-tao. Expression of heme oxygenase-1 induced by doxorubicin in liver，spleen， and kidney and effect of doxorubicin on liver function [J]. J4, 2004, 30(1): 82-84.